Drug intelligence / Profile preview

Aiyingda

Development stage
Preclinical
Lead developer
罗益
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

**Aiyingda** is a pediatric combined vaccine developed by Luoyi Wuxi Biopharmaceutical for prevention of invasive disease caused by *Neisseria meningitidis* serogroups A and C and *Haemophilus influenzae* type b. It contains meningococcal capsular polysaccharide antigens from serogroups A and C together with a Hib conjugate antigen. The product is intended to induce antigen-specific protective immune responses, including antibodies against the relevant bacterial capsular polysaccharides. A randomized open-label study in healthy children aged 12–23 months evaluated one-dose and two-dose schedules for immunogenicity, immune persistence, and safety.

Brand names
Aiyingda
Other names
AC-Hib combined vaccineGroup A and C meningococcal polysaccharide and Haemophilus influenzae type b conjugate vaccine
02

Targets

NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharidePRNP (Cellular Prion Protein)

Beyond the preview

Go deeper on Aiyingda.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aiyingda.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call